Dianosic
Dianosic is a biotech company dedicated to designing transformative intranasal solutions that improve patient quality of life and support rapid recovery. They focus on innovative drug delivery platforms for chronic rhinitis, rhinosinusitis, and intranasal bleeding, with ambitions to expand into central nervous system diseases. Their mission is to develop patient-centric, minimally invasive, long-term resorbable solutions that enhance treatment efficacy, safety, and adherence.
Industries
Nr. of Employees
small (1-50)
Dianosic
Head Office: 8 place de l’Hôpital, 67000 Strasbourg, France; Paris: 4 Pl. Saint-Germain des Prés, 75006 Paris, France
Patents
Products
Active resorbable intranasal scaffold — chronic rhinitis (ARIS‑R program)
An implantable, bioresorbable scaffold designed to deliver a low dose of corticosteroid locally in the nasal cavity for approximately six months to treat persistent moderate-to-severe allergic rhinitis.
Active resorbable intranasal scaffold — chronic rhinosinusitis (ARIS‑S program)
An implantable, bioresorbable scaffold intended to provide local corticosteroid delivery for up to 12 months to manage symptoms of chronic rhinosinusitis in adults.
Nose‑to‑brain intranasal delivery program (NTB)
An R&D program exploring intranasal formulations and delivery concepts intended to deliver therapeutic agents to the central nervous system via nasal routes, leveraging drug‑eluting polymer scaffold know‑how.
Asymmetric intranasal inflatable balloon for epistaxis management (intranasal tamponade device)
A minimally invasive asymmetric intranasal inflatable device designed to control anterior and posterior nasal bleeding with features for atraumatic insertion, an anti‑migration disk, a hollow breathing channel and deployment markers.
Active resorbable intranasal scaffold — chronic rhinitis (ARIS‑R program)
An implantable, bioresorbable scaffold designed to deliver a low dose of corticosteroid locally in the nasal cavity for approximately six months to treat persistent moderate-to-severe allergic rhinitis.
Active resorbable intranasal scaffold — chronic rhinosinusitis (ARIS‑S program)
An implantable, bioresorbable scaffold intended to provide local corticosteroid delivery for up to 12 months to manage symptoms of chronic rhinosinusitis in adults.
Nose‑to‑brain intranasal delivery program (NTB)
An R&D program exploring intranasal formulations and delivery concepts intended to deliver therapeutic agents to the central nervous system via nasal routes, leveraging drug‑eluting polymer scaffold know‑how.
Asymmetric intranasal inflatable balloon for epistaxis management (intranasal tamponade device)
A minimally invasive asymmetric intranasal inflatable device designed to control anterior and posterior nasal bleeding with features for atraumatic insertion, an anti‑migration disk, a hollow breathing channel and deployment markers.
Services
Provision of procedural steps, instructional videos, webinars and an augmented‑reality mobile application to train healthcare professionals on device use and procedures.
A clinician-facing forum and clinical case submission process to share real‑world cases, best practices and procedural feedback.
Provision of procedural steps, instructional videos, webinars and an augmented‑reality mobile application to train healthcare professionals on device use and procedures.
A clinician-facing forum and clinical case submission process to share real‑world cases, best practices and procedural feedback.
Expertise Areas
- Intranasal drug delivery
- Implantable resorbable scaffold development
- Epistaxis (intranasal bleeding) device therapy
- Formulation development for sustained release
Key Technologies
- Drug‑eluting resorbable polymers
- Biodegradable polymer scaffolds
- Sustained‑release formulation
- Intranasal scaffold architecture
News & Updates
Dianosic launches a WiSEED backed convertible bonds transaction to accelerate innovation in the treatment of chronic allergic rhinitis. This initiative aims to support the development of their ARIS program, an innovative intranasal scaffold designed to transform the treatment of chronic allergic rhinitis and rhinosinusitis, with potential applications in neurodegenerative and neuropsychiatric diseases.
Dianosic is nominated for the 2024 edition of the 'Trophées des entreprises d’Alsace', recognizing their commitment to innovation and impact in the region. The awards ceremony will be held in Strasbourg with notable attendees.
Dianosic has joined France Deeptech, a network of research labs, startups, and partners supporting deeptech innovation in Europe. This integration opens opportunities for collaboration and development in advanced biotech and medtech fields.
Dianosic successfully raised €4.7 million to advance clinical trials for their chronic rhinitis treatment device, marking a significant milestone in their development.
Dianosic was awarded at the prestigious i-Lab 2019 contest organized by the French Ministry of Higher Education and Research, recognizing their innovative biotech solutions.
Dianosic was recognized as a top innovative startup by the French government, boosting visibility and credibility in biotech.
Dianosic launches a WiSEED backed convertible bonds transaction to accelerate innovation in the treatment of chronic allergic rhinitis. This initiative aims to support the development of their ARIS program, an innovative intranasal scaffold designed to transform the treatment of chronic allergic rhinitis and rhinosinusitis, with potential applications in neurodegenerative and neuropsychiatric diseases.
Dianosic is nominated for the 2024 edition of the 'Trophées des entreprises d’Alsace', recognizing their commitment to innovation and impact in the region. The awards ceremony will be held in Strasbourg with notable attendees.
Dianosic has joined France Deeptech, a network of research labs, startups, and partners supporting deeptech innovation in Europe. This integration opens opportunities for collaboration and development in advanced biotech and medtech fields.
Dianosic successfully raised €4.7 million to advance clinical trials for their chronic rhinitis treatment device, marking a significant milestone in their development.
Dianosic was awarded at the prestigious i-Lab 2019 contest organized by the French Ministry of Higher Education and Research, recognizing their innovative biotech solutions.
Dianosic was recognized as a top innovative startup by the French government, boosting visibility and credibility in biotech.